Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week

One of the top-performing healthcare stocks mid-week was Corcept Therapeutics (CORT 2.41%), and it was little wonder -- the company was granted U.S. Food and Drug Administration (FDA) approval for its leading drug candidate.The double-digit pop Corcept experienced wasn't sustainable, as some investors booked quick profits after learning of the nod. Still, the stock landed in positive territory, posting a gain of just under 9% over the course of the week, according to data compiled by S&P Global Market Intel ...